Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE (PAR: OSE) launches AI immunotherapy partnership
Published by Arron Aatkar, PhD

OSE has signed a strategic partnership with Scienta Lab, aiming to model inflammatory diseases and identify predictive biomarkers of efficacy for immunotherapies. Scienta Lab is a France-based leader in AI-driven precision immunology, and under this agreement, it will be employing its AI-powered multimodal foundation model dedicated to translational immunology research. Ultimately, OSE believes this partnership will support the development of tailored immunotherapies and drive more favourable outcomes for patients with immune-mediated inflammatory conditions.

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO